HDAC9 and Miyoshi myopathy: Exploiting well-known pathways is an effective approach but, most importantly, the understanding of MM’s pathophysiological mechanisms has led to the discovery of different therapeutic targets on plasma cells, and favored the development of completely new molecules, such as XPO1 inhibitors or HDAC inhibitors.